search
Back to results

SlimShape Device for Abdominal Fat and Circumference Reduction

Primary Purpose

Fat Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SlimShape
Sponsored by
Syneron Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fat Disorder focused on measuring lipolysis, fat reduction, circumference reduction

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Signed informed consent to participate in the study.
  2. Female and male subjects, ≥18 and ≤60 years of age at the time of enrollment
  3. Fitzpatrick Skin Type I to VI
  4. BMI interval: 18.5 ≤ BMI ≤ 30 (normal to overweight, but not obese).
  5. If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
  6. In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
  7. General good health confirmed by medical history and skin examination of the treated area.
  8. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
  9. Willing to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
  10. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

Exclusion Criteria:

  1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism
  2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
  3. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
  4. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
  5. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone
  6. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction
  7. Previous body contouring procedures in the treatment area within 12 months
  8. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
  9. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity)
  10. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
  11. Allergy to any component of the lotion (VelaSpray Ease) used in this study
  12. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
  13. Very poor skin quality (i.e., severe laxity)
  14. Abdominal wall diastasis or hernia on physical examination
  15. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
  16. Obesity (BMI > 30)
  17. Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study
  18. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
  19. Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration).
  20. Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s).
  21. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Sites / Locations

  • Laser & Skin Surgery Medical Group, Inc
  • Syneron Candela Institute for Education Clinic
  • Union Square Laser Dermatology
  • Laser & Skin Surgery Center of New York

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Abdominal fat reduction treatment

Arm Description

SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.

Outcomes

Primary Outcome Measures

Change in Fat Thickness at Final Follow-up Compared to Baseline
Abdominal fat change, measured by ultrasound, post SlimShape treatments at 12 weeks follow-up (12wk FU) compared to baseline

Secondary Outcome Measures

Change in Fat Thickness After Treatments Compared to Baseline
Abdominal fat change, measured by ultrasound, post SlimShape treatments at 4 and 8 weeks follow-up after final treatment compared to baseline
Change in Abdominal Circumference After Treatments Compared to Baseline
Change in abdominal circumference, measured by calibrated measuring tape, at 4, 8 and 12 weeks follow-up (after final treatment) compared to baseline

Full Information

First Posted
December 19, 2016
Last Updated
April 4, 2019
Sponsor
Syneron Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT02999763
Brief Title
SlimShape Device for Abdominal Fat and Circumference Reduction
Official Title
Clinical Study to Evaluate the Safety and Efficacy of the SlimShape Device for Abdominal Fat and Circumference Reduction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
January 13, 2017 (Actual)
Primary Completion Date
May 3, 2018 (Actual)
Study Completion Date
August 7, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Syneron Medical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective, one-arm, baseline-controlled, clinical study for the evaluation of the SlimShape device for non-invasive abdominal fat and circumference reduction. Study subjects will undergo SlimShape treatments on the abdominal area.
Detailed Description
The objective of this trial is to evaluate the safety and efficacy of the SlimShape device utilizing the SlimShape Applicator Belt for abdominal non-invasive fat and circumference reduction. Eligible subjects will receive up to 3 bi-weekly treatments (2 weeks interval) with the SlimShape device utilizing the SlimShape Applicator Belt according to the study protocol. The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment. Each subject will be enrolled for total expected study duration of up to 16 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fat Disorder
Keywords
lipolysis, fat reduction, circumference reduction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Abdominal fat reduction treatment
Arm Type
Experimental
Arm Description
SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
Intervention Type
Device
Intervention Name(s)
SlimShape
Intervention Description
SlimShape radiofrequency treatment to the abdomen
Primary Outcome Measure Information:
Title
Change in Fat Thickness at Final Follow-up Compared to Baseline
Description
Abdominal fat change, measured by ultrasound, post SlimShape treatments at 12 weeks follow-up (12wk FU) compared to baseline
Time Frame
Baseline and 12 weeks follow-up
Secondary Outcome Measure Information:
Title
Change in Fat Thickness After Treatments Compared to Baseline
Description
Abdominal fat change, measured by ultrasound, post SlimShape treatments at 4 and 8 weeks follow-up after final treatment compared to baseline
Time Frame
Baseline and 4 and 8 weeks follow-up
Title
Change in Abdominal Circumference After Treatments Compared to Baseline
Description
Change in abdominal circumference, measured by calibrated measuring tape, at 4, 8 and 12 weeks follow-up (after final treatment) compared to baseline
Time Frame
At 4 weeks, 8 weeks and 12 weeks follow-up (post last treatment)
Other Pre-specified Outcome Measures:
Title
Number of Treatments Where Participants Reported Having "Mild", "Moderate" or "Severe" Response
Description
Discomfort and immediate response will be assessed immediately after each treatment using the Post Treatment Immediate Response severity scale (Absent/none, Mild, Moderate and Severe). The values in the data table reflect the number of participants who had discomfort during treatment or immediate response after treatment (reported as having "Mild", "Moderate" or "Severe" )
Time Frame
First, second and third treatments, Weeks 0 to 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed informed consent to participate in the study. Female and male subjects, ≥18 and ≤60 years of age at the time of enrollment Fitzpatrick Skin Type I to VI BMI interval: 18.5 ≤ BMI ≤ 30 (normal to overweight, but not obese). If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence). In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause). General good health confirmed by medical history and skin examination of the treated area. Willing to follow the treatment and follow-up schedule and post-treatment care instructions. Willing to refrain from a change in diet/ exercise/medication regimen for the entire course of the study. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations. Exclusion Criteria: History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction Previous body contouring procedures in the treatment area within 12 months History of skin disease in the treatment area, known tendency to form keloids or poor wound healing History of epidermal or dermal disorders (particularly if involving collagen or microvascularity) Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course Allergy to any component of the lotion (VelaSpray Ease) used in this study Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area Very poor skin quality (i.e., severe laxity) Abdominal wall diastasis or hernia on physical examination Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months Obesity (BMI > 30) Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months) Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration). Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s). As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ruthie Amir, MD
Organizational Affiliation
Syneron Medical
Official's Role
Study Director
Facility Information:
Facility Name
Laser & Skin Surgery Medical Group, Inc
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Syneron Candela Institute for Education Clinic
City
Wayland
State/Province
Massachusetts
ZIP/Postal Code
01778
Country
United States
Facility Name
Union Square Laser Dermatology
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Facility Name
Laser & Skin Surgery Center of New York
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24687404
Citation
Adatto MA, Adatto-Neilson RM, Morren G. Reduction in adipose tissue volume using a new high-power radiofrequency technology combined with infrared light and mechanical manipulation for body contouring. Lasers Med Sci. 2014 Sep;29(5):1627-31. doi: 10.1007/s10103-014-1564-x. Epub 2014 Apr 1.
Results Reference
background

Learn more about this trial

SlimShape Device for Abdominal Fat and Circumference Reduction

We'll reach out to this number within 24 hrs